Immunovia announced that the company will move its lab and U.S. headquarters to Research Triangle Park in North Carolina in May 2024. The move to Research Triangle Park follows the company?s successful model development study, announced on April 22, 2024, and the successful completion of the discovery phase for its next-generation test in November 2023. Following these successes, the company will focus on confirming the analytical validity of its new test and conducting a large clinical validation study.

This work will be conducted at the lab in Research Triangle Park under the leadership and direction of Dr. Lisa Ford. Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy the company announced in July 2023 to streamline operations and reduce costs. The new space in Research Triangle Park (RTP) will be significantly smaller and less expensive than the company's existing lab in Marlborough, Massachusetts.

The lower cost of labor in Research Triangle Park should enable the company to staff the new lab at a lower cost.